Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase II trial to study the safety and tolerability of subcutaneous alemtuzumab
administered without dose escalation to patients with advanced B-cell chronic lymphocytic
leukemia (B-CLL).